Compositions and methods of use for extracts of magnoliaceae plants
Abstract
The invention relates to compositions and methods for preventing, treating, or managing sleeplessness, restlessness, weight gain including weight gain due to stress or lack of sleep, or all three comprising the administration of a prophylactically and therapeutically effective amount of Magnoliaceae plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is human and the compositions have comprise at least two compounds selected from magnolol, honokiol, and magnoflorine. Alternatively, the compositions may also comprise about 2% honokiol by weight of the composition.
Claims
exact text as granted — not AI-modified1 - 45 . (Cancelled)
46 . A pharmaceutical composition for human use comprising a Magnoliaceae plant extract, the Magnoliaceae plant extract being present in an amount from about 25% to about 100% by weight of the pharmaceutical composition.
47 . The pharmaceutical composition of claim 46 wherein said Magnoliaceae plant extract is present in an amount from about 35% to about 90% by weight of the pharmaceutical composition.
48 . The pharmaceutical composition of claim 47 wherein the Magnoliaceae plant extract is present in an amount from about 40% to about 80% by weight of the pharmaceutical composition.
49 . A pharmaceutical composition for human use comprising a Magnoliaceae plant extract, the Magnoliaceae plant extract being present in an amount from about 4 mg to about 12.5 mg per kg of body weight of said human.
50 . The pharmaceutical composition of claim 49 wherein said Magnoliaceae plant extract is present in an amount from about 5 mg to about 11 mg per kg of body weight of said human.
51 . The composition of claim 46 wherein said pharmaceutical composition is suitable for parenteral or oral administration to said human.
52 . The pharmaceutical composition of claim 49 wherein the pharmaceutical composition is suitable for parenteral or oral administration to said human.
53 . The pharmaceutical composition of claim 46 wherein the Magnoliaceae plant belongs to the genus Liriodendron or Magnolia.
54 . The pharmaceutical composition of claim 49 wherein the Magnoliaceae plant belongs to the genus Liriodendron or Magnolia.
55 . A food composition comprising a Magnoliaceae plant extract, the Magnoliaceae plant extract being present in an amount from about 0.1% to about 50% by weight of the food composition.
56 . The composition of claim 55 wherein the Magnoliaceae plant extract is present in an amount from about 1% to about 10% by weight of the food composition.
57 . The composition of claim 55 wherein the Magnoliaceae plant belongs to the genus Liriodendron or Magnolia.
58 . The pharmaceutical composition of claim 46 further comprising a pharmaceutically acceptable carrier or excipient.
59 . The pharmaceutical composition of claim 49 further comprising a pharmaceutically acceptable carrier or excipient.
60 . The composition of claim 46 wherein said Magnoliaceae plant extract comprises at least two compounds selected from the group consisting of magnolol, honokiol, magnoflorine.
61 . The composition of claim 49 wherein said Magnoliaceae plant extract comprises at least two compounds selected from the group consisting of magnolol, honokiol, magnoflorine wherein honokiol is present in an amount of about 2% by weight of the pharmaceutical composition.
62 . The food composition of claim 55 wherein the Magnoliaceae plant extract comprises at least two compounds selected from the group consisting of magnolol, honokiol, magnoflorine.
63 . The composition of claim 55 . wherein when honokiol is present, said honokiol is present in an amount of about 2% by weight of the Magnoliaceae plant extract.Join the waitlist — get patent alerts
Track US2004228934A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.